EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Design, synthesis, and antiproliferative activity of new indole/1,2,4‐triazole/chalcone hybrids as EGFR and/or c‐MET inhibitors

Esraa Mahmoud, Dalia Abdelhamid iD, Bahaa G M Youssif, Hesham A M Gomaa, Alaa M Hayallah, Mohamad Abdel-Aziz

Archiv der Pharmazie · 2024

DOI: 10.1002/ardp.202300562 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Archiv der Pharmazie, 2024. Verfasst von Esraa Mahmoud und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Deraya University, Minia, Egypt. Hauptthemen laut MEDLINE: ErbB Receptors, Proto-Oncogene Proteins c-met, Antineoplastic Agents, Cell Proliferation. Die Arbeit wurde bisher 23-mal zitiert (Crossref) und nennt 70 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: None.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

A novel group of indolyl‐1,2,4‐triazole‐chalcone hybrids was designed, synthesized, and assessed for their anticancer activity. The synthesized compounds exhibited significant antiproliferative activity. Compounds 9a and 9e exhibited significant cancer inhibition with GI 50 ranging from 3.69 to 20.40 µM and from 0.29 to >100 µM, respectively. Both compounds displayed a broad spectrum of anticancer activity with selectivity ratios ranging between 0.50–2.78 and 0.25–2.81 at the GI 50 level, respectively. The synthesized compounds were also screened for their cytotoxicity by 3‐(4,5‐dimethylthiazole‐2‐yl)‐2,5‐diphenyltetrazol (MTT) assay and for inhibition of epidermal growth factor receptor (EGFR) and c‐MET (mesenchymal‐epithelial transition factor). Some of the tested compounds exhibited significant inhibition against EGFR and/or c‐MET. Compound 9b showed the highest c‐MET inhibition (IC 50 = 4.70 nM) compared to foretinib (IC 50 = 2.5 nM). Compound 9d showed equipotent activity compared with erlotinib against EGFR (IC 50 = 0.052 µM) and displayed significant c‐MET inhibition with an IC 50 value of 4.90 nM.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ErbB ReceptorsProto-Oncogene Proteins c-metAntineoplastic AgentsCell ProliferationTriazolesDrug DesignProtein Kinase InhibitorsDrug Screening Assays, AntitumorIndolesHumansStructure-Activity RelationshipDose-Response Relationship, DrugMolecular StructureCell Line, TumorChalconesChalcone

Stichwörter der Autor:innen

EGFRchalconec‐Metindoletriazole

Substanzen

ErbB ReceptorsProto-Oncogene Proteins c-metAntineoplastic AgentsTriazolesEGFR protein, humanProtein Kinase InhibitorsIndoles1,2,4-triazoleMET protein, humanChalcones

Autor:innen und Institutionen

  • Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Deraya University, Minia, Egypt.
  • Department of Medicinal Chemistry, Faculty of Pharmacy, Minia University, Minia, Egypt.
  • Raabe College of Pharmacy, Ohio Northern University, Ohio, USA.
  • Department of Pharmaceutical Organic Chemistry, Faculty of Pharmacy, Assiut University, Assiut, Egypt.
  • Pharmacology Department, College of Pharmacy, Jouf University, Sakaka, Saudi Arabia.
  • Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Sphinx University, New-Assiut, Egypt.

ORCID-Profile: Dalia Abdelhamid

Förderung

  • None

Zitieren

APA

Mahmoud, E., Abdelhamid, D., Youssif, B. G. M., Gomaa, H. A. M., Hayallah, A. M., & Abdel-Aziz, M. (2024). Design, synthesis, and antiproliferative activity of new indole/1,2,4‐triazole/chalcone hybrids as EGFR and/or c‐MET inhibitors. Archiv der Pharmazie. https://doi.org/10.1002/ardp.202300562

Vancouver

Mahmoud E, Abdelhamid D, Youssif BGM, Gomaa HAM, Hayallah AM, Abdel-Aziz M. Design, synthesis, and antiproliferative activity of new indole/1,2,4‐triazole/chalcone hybrids as EGFR and/or c‐MET inhibitors. Archiv der Pharmazie. 2024. doi:10.1002/ardp.202300562

BibTeX
@article{Mahmoud2024,
  author = {Mahmoud, Esraa and Abdelhamid, Dalia and Youssif, Bahaa G M and Gomaa, Hesham A M and Hayallah, Alaa M and Abdel-Aziz, Mohamad},
  title = {Design, synthesis, and antiproliferative activity of new indole/1,2,4‐triazole/chalcone hybrids as EGFR and/or c‐MET inhibitors},
  journal = {Archiv der Pharmazie},
  year = {2024},
  doi = {10.1002/ardp.202300562}
}
Kostenlos starten →